Searching News Database: Muscular Dystrophy
HSMN NewsFeed - 4 Dec 2020
PTC Announces Translarna(TM) Approval in Russia for the Treatment of Duchenne Muscular Dystrophy
PTC Announces Translarna(TM) Approval in Russia for the Treatment of Duchenne Muscular Dystrophy
HSMN NewsFeed - 2 Dec 2019
Cumberland Pharmaceuticals Receives FDA Approval for RediTrex(TM) Product Line
Cumberland Pharmaceuticals Receives FDA Approval for RediTrex(TM) Product Line
HSMN NewsFeed - 15 Oct 2019
World Renowned Experts Appointed to Skyhawk Therapeutics Scientific Advisory Board
World Renowned Experts Appointed to Skyhawk Therapeutics Scientific Advisory Board
HSMN NewsFeed - 29 Nov 2017
Capricor Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for CAP-1002
Capricor Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for CAP-1002
HSMN NewsFeed - 20 Nov 2017
United Therapeutics Announces Additional Six Months Of Regulatory Exclusivity For Adcirca(R)
United Therapeutics Announces Additional Six Months Of Regulatory Exclusivity For Adcirca(R)
HSMN NewsFeed - 11 Jul 2017
Nuredis Appoints Julie Anne Smith as Chief Executive Officer to Lead Neurodegenerative Disease Company
Nuredis Appoints Julie Anne Smith as Chief Executive Officer to Lead Neurodegenerative Disease Company
HSMN NewsFeed - 30 May 2017
AMO Pharma Announces FDA Fast Track Designation For AMO-02 For Treatment Of Congenital Myotonic Dystrophy
AMO Pharma Announces FDA Fast Track Designation For AMO-02 For Treatment Of Congenital Myotonic Dystrophy
HSMN NewsFeed - 3 Apr 2017
aTyr Pharma Announces Appointment of Jeffery S. Hatfield to its Board of Directors
aTyr Pharma Announces Appointment of Jeffery S. Hatfield to its Board of Directors
HSMN NewsFeed - 26 Dec 2016
SPINRAZA(TM) (nusinersen) Approved in U.S. to Treat Broad Range of Patients with Spinal Muscular Atrophy
SPINRAZA(TM) (nusinersen) Approved in U.S. to Treat Broad Range of Patients with Spinal Muscular Atrophy
HSMN NewsFeed - 7 Sep 2016
FDA allows Phrixus’s IND for Carmeseal-MD(TM) (P-188 NF) in Duchenne muscular dystrophy (DMD)
FDA allows Phrixus’s IND for Carmeseal-MD(TM) (P-188 NF) in Duchenne muscular dystrophy (DMD)
HSMN NewsFeed - 25 Aug 2016
Mallinckrodt Receives FDA Fast-Track Designation for Synacthen(R) Depot IND Application
Mallinckrodt Receives FDA Fast-Track Designation for Synacthen(R) Depot IND Application
HSMN NewsFeed - 5 May 2016
aTyr Pharma Appoints Grove Matsuoka as Senior Vice President, Product Programs and Planning
aTyr Pharma Appoints Grove Matsuoka as Senior Vice President, Product Programs and Planning
HSMN NewsFeed - 23 Feb 2016
PTC Receives Refuse to File Letter from FDA for Translarna(TM) (ataluren)
PTC Receives Refuse to File Letter from FDA for Translarna(TM) (ataluren)
HSMN NewsFeed - 27 Oct 2015
Transgenomic Launches New Genetic Testing Service for Diagnosis of Charcot-Marie-Tooth Syndrome
Transgenomic Launches New Genetic Testing Service for Diagnosis of Charcot-Marie-Tooth Syndrome
HSMN NewsFeed - 20 Jul 2015
BioMarin Provides Program Update for Talazoparib in Metastatic Breast Cancer
BioMarin Provides Program Update for Talazoparib in Metastatic Breast Cancer
HSMN NewsFeed - 8 Apr 2015
PTC Therapeutics Names Eric Pauwels SVP & General Manager Commercial Operations, Americas
PTC Therapeutics Names Eric Pauwels SVP & General Manager Commercial Operations, Americas
HSMN NewsFeed - 18 Feb 2015
aTyr Pharma Receives EMA Orphan Drug Designation for Resolaris(TM) in FSHD
aTyr Pharma Receives EMA Orphan Drug Designation for Resolaris(TM) in FSHD
HSMN NewsFeed - 3 Jul 2014
Akashi Therapeutics Receives Collective Funding of $1.5 Million to Support HT-100 Clinical Development
Akashi Therapeutics Receives Collective Funding of $1.5 Million to Support HT-100 Clinical Development
HSMN NewsFeed - 31 Dec 2013
Agilis Biotherapeutics Completes $8 Million Financing to Develop DNA-based Therapeutics for Rare Diseases
Agilis Biotherapeutics Completes $8 Million Financing to Develop DNA-based Therapeutics for Rare Diseases
HSMN NewsFeed - 30 Dec 2013
Electromed, Inc. Receives FDA Market Clearance for the SmartVest(R) SQL(TM)
Electromed, Inc. Receives FDA Market Clearance for the SmartVest(R) SQL(TM)
HSMN NewsFeed - 21 Nov 2013
Eloxx Pharmaceuticals, Ltd. Announced the Initial Closing of its First Round of Financing
Eloxx Pharmaceuticals, Ltd. Announced the Initial Closing of its First Round of Financing
HSMN NewsFeed - 28 Sep 2012
PTC Therapeutics Appoints Jerome B. Zeldis, M.D., Ph.D. to Board of Directors
PTC Therapeutics Appoints Jerome B. Zeldis, M.D., Ph.D. to Board of Directors
HSMN NewsFeed - 9 Dec 2011
AVI BioPharma Names Jayant Aphale, Ph.D., Senior Vice President of Technical Operations
AVI BioPharma Names Jayant Aphale, Ph.D., Senior Vice President of Technical Operations
HSMN NewsFeed - 8 Jul 2011
Amsterdam Molecular Therapeutics Files Glybera(R) European Marketing Application for Re-examination
Amsterdam Molecular Therapeutics Files Glybera(R) European Marketing Application for Re-examination
HSMN NewsFeed - 24 Jun 2011
Amsterdam Molecular Therapeutics Receives Opinion on Glybera(R) Marketing Authorisation Application
Amsterdam Molecular Therapeutics Receives Opinion on Glybera(R) Marketing Authorisation Application
HSMN NewsFeed - 7 Jan 2011
AVI Biopharma Names Effie Toshav Senior Vice President and General Counsel
AVI Biopharma Names Effie Toshav Senior Vice President and General Counsel
HSMN NewsFeed - 9 Sep 2010
Shire Expands Pipeline to Treat Orphan Muscle Diseases Through Collaboration With Acceleron Pharma
Shire Expands Pipeline to Treat Orphan Muscle Diseases Through Collaboration With Acceleron Pharma
HSMN NewsFeed - 24 May 2010
Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich's Ataxia
Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich's Ataxia
HSMN NewsFeed - 13 Oct 2009
AMT Receives EMEA Orphan Drug Designation for Duchenne Muscular Dystrophy
AMT Receives EMEA Orphan Drug Designation for Duchenne Muscular Dystrophy
HSMN NewsFeed - 10 Sep 2009
StemCells, Inc. to Initiate First Ever Neural Stem Cell Trial in Myelination Disorder
StemCells, Inc. to Initiate First Ever Neural Stem Cell Trial in Myelination Disorder
HSMN NewsFeed - 10 Sep 2009
PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis
PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis
HSMN NewsFeed - 28 Jul 2008
AVI BioPharma Appoints New Senior Vice President and Chief Financial Officer
AVI BioPharma Appoints New Senior Vice President and Chief Financial Officer
HSMN NewsFeed - 1 Nov 2007
AVI BioPharma Receives Orphan Drug Designation for AVI-4658 for Treatment of Duchenne Muscular Dystrophy
AVI BioPharma Receives Orphan Drug Designation for AVI-4658 for Treatment of Duchenne Muscular Dystrophy
HSMN NewsFeed - 20 Feb 2007
Stem Cell Sciences Licenses Neural Stem Cell Technology to Merck & Co., Inc.
Stem Cell Sciences Licenses Neural Stem Cell Technology to Merck & Co., Inc.
HSMN NewsFeed - 10 Jan 2007
Italian Ministry of Health Requests IPLEX(TM) for Treatment of ALS (Lou Gehrig's Disease)
Italian Ministry of Health Requests IPLEX(TM) for Treatment of ALS (Lou Gehrig's Disease)
HSMN NewsFeed - 3 Nov 2006
PTC Therapeutics Announces Positive Phase 2 Results For PTC124 in Cystic Fibrosis
PTC Therapeutics Announces Positive Phase 2 Results For PTC124 in Cystic Fibrosis
HSMN NewsFeed - 21 Oct 2006
PTC Therapeutics Announces Encouraging Preliminary Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
PTC Therapeutics Announces Encouraging Preliminary Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
HSMN NewsFeed - 20 Jul 2006
Stem Cell Therapy International Names Lixian (John) Jiang, Chief Operating Officer, China Division
Stem Cell Therapy International Names Lixian (John) Jiang, Chief Operating Officer, China Division
Additional items found! 46
Members Archive contains
46 additional stories matching:
Muscular Dystrophy
(Password required)
Muscular Dystrophy
(Password required)